Project description
Novel AMD treatment development
Dry age-related macular degeneration (AMD) is a significant cause of vision loss, and since there is currently no available treatment, early intervention can help slow its progression, thereby preserving both vision and quality of life. OphtiMedRx, a start-up focused on ophthalmic drug development and led by a team of accomplished female physicians and scientists, is actively working on a novel drug for the treatment of AMD. This drug candidate specifically targets cell senescence and can be administered via intravitreal (IVT) injection in a clinical setting without requiring hospitalisation. Phase I clinical trials are scheduled for late 2024. The EU-funded OPTM.RX project will allocate this grant towards consultant fees, a specialised regulatory firm, and FDA/EMA fees.
Objective
OphtiMedRx is an ophthalmic drug development start-up company led by a team of exceptional women physicians and scientists led by Dr. Dana Rabinovich. OphtiMedRx is developing a novel drug for treating dry age-related macular degeneration (AMD), a leading cause of vision loss. There is no available treatment for dry AMD, which affects 8.7% of the population and a further 2 million diagnosed yearly. The occurrence of AMD steadily increases with age, affecting 2% of the population at age 40 and 20% of people over 75. Our drug candidate, delivered by intravitreal (IVT) injection in a clinic setting without hospitalization, targets cellular aging, termed cell senescence. Our product addresses the underlying cause of dry AMD, allowing for early intervention. Targeting the disease at early stages will halt, or significantly slow, dry AMD progression, preserving vision and maintaining quality of life. We are currently performing preclinical R&D studies and plan to be ready for Phase I clinical trials by the end of 2024. A crucial step toward clinical trials is conducting a pre-Investigational New Drug (IND) meeting with the FDA and a scientific advice meeting with EMA officials. These meetings are an opportunity to gain the agency’s feedback on the design of the proposed nonclinical and clinical studies. Additionally, these meetings will help us determine the budget and timeline for transitioning towards phase I clinical trials, as well as set a goal for the next fundraising round. The financial contribution of this grant will go towards consultant fees, a specialized regulatory firm, and FDA/EMA fees. In addition, as a new CEO, I would greatly benefit from the mentoring and coaching provided by EIC’s Business Acceleration Services, which will help me improve my professional skill set, particularly in investor relations, and assist me with my various management and leadership challenges.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineophthalmology
You need to log in or register to use this function
Programme(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
1290000 Katzrin
Israel